Market Overview:
The global prophylactic HIV drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of HIV/AIDS, rising awareness about prophylactic drugs, and technological advancements in the field of prophylactic drugs. The global prophylactic HIV drug market can be segmented on the basis of type into nucleoside or nucleotide reverse transcriptase inhibitors (NRTI) and integrase inhibitors. The NRTI segment is expected to dominate the global prophylactic HIV drug market during the forecast period owing to their high efficacy and safety profile.
Product Definition:
A prophylactic HIV drug is a medication that is taken to prevent the transmission of HIV. It can be used by people who are at risk for exposure to the virus, such as those who are having sex with multiple partners or those who use intravenous drugs. The importance of prophylactic HIV drugs is that they can help prevent the spread of the virus and potentially save lives.
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI):
NRTIs are a class of anti-retroviral drugs used to treat HIV infection. NRTIs inhibit reverse transcriptase activity, thereby preventing the conversion of HIV-1 viral DNA into its complementary RNA form. The drug class includes Efudexant (EFV), Delavirdine (LDV), and Reteplase.
Integrase Inhibitor:
The integrase inhibitor is a drug that prevents the reverse transcriptase from transcribing viral genes into DNA. The integrase inhibitors are used for the treatment of HIV infection. Currently, only one drug has been approved by the U.S FDA under this category, namely raltegravir (Isentress). It was approved in 2007 and currently remains as one of the few anti-HIV drugs available commercially.
Application Insights:
Based on application, the global prophylactic HIV drug market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The online pharmacies dominated the market in 2017 owing to factors such as increasing internet users globally and growing awareness about safe sex practices. Moreover, an increase in prevalence of HIV among adults coupled with a rise in demand for pre-exposure prophylaxis (PrEP) is expected to drive growth over the forecast period.
The hospital pharmacist plays an important role in dispensing drugs that are used for preventing infections caused by pathogenic microorganisms at hospitals or healthcare facilities. This segment accounted for a major share due to high usage of antiretrovirals among patients admitted at hospitals worldwide since 1996 when highly active antiretroviral therapy (HAART) was introduced; this factor also contributes towards growth of other segments such as retail pharmacies and online pharmacies due to easy availability of drugs through these channels.
Regional Analysis:
North America dominated the global prophylactic HIV drug market in 2016 with a revenue share of over 40%. The presence of effective healthcare infrastructure, high disposable income, and awareness campaigns by various organizations are some factors attributing to this dominance. Moreover, the availability of these drugs through online pharmacies is further augmenting their adoption across this region.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to increasing prevalence levels and growing demand for prophylactic drugs in countries such as India and China. Furthermore, rising government initiatives for tackling HIV/AIDS are also driving regional growth. For instance, according to WHO statistics published in 2017; around 6 million people were living with HIV-1 infection worldwide (excluding Western Asia) accounting for 22% of all those infected globally while 1 million deaths were reported from AIDS related causes (excluding Western Asia).
Growth Factors:
- Increasing incidence of HIV/AIDS: The global incidence of HIV is on the rise, with an estimated 36.7 million people living with the virus in 2017. This is expected to drive demand for prophylactic HIV drugs over the forecast period.
- Growing awareness about prophylactic drugs: There is a growing awareness among people about the benefits of prophylactic drugs in preventing HIV infection. This is likely to boost demand for these drugs in the coming years.
- Rising prevalence of unprotected sex: Unprotected sex continues to be a major risk factor for contracting HIV, which is likely to fuel demand for prophylactic AIDS drugs over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Prophylactic HIV Drug Market Research Report
By Type
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI), Integrase Inhibitor
By Application
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
By Companies
Gilead Sciences, Merck, Mylan, Cipla, Bristol-Myers Squibb, Roche
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Prophylactic HIV Drug Market Report Segments:
The global Prophylactic HIV Drug market is segmented on the basis of:
Types
Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI), Integrase Inhibitor
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead Sciences
- Merck
- Mylan
- Cipla
- Bristol-Myers Squibb
- Roche
Highlights of The Prophylactic HIV Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
- Integrase Inhibitor
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prophylactic HIV Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A prophylactic HIV drug is a medication taken by people who are at risk of getting HIV, in order to prevent the virus from attacking their cells and causing AIDS. Prophylactic drugs can be used before exposure to the virus, during early stages of infection, or after exposure but before symptoms appear.
Some of the major companies in the prophylactic hiv drug market are Gilead Sciences, Merck, Mylan, Cipla, Bristol-Myers Squibb, Roche.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Prophylactic HIV Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Prophylactic HIV Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Prophylactic HIV Drug Market - Supply Chain
4.5. Global Prophylactic HIV Drug Market Forecast
4.5.1. Prophylactic HIV Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Prophylactic HIV Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Prophylactic HIV Drug Market Absolute $ Opportunity
5. Global Prophylactic HIV Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Prophylactic HIV Drug Market Size and Volume Forecast by Type
5.3.1. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
5.3.2. Integrase Inhibitor
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Prophylactic HIV Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Prophylactic HIV Drug Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacy
6.3.2. Retail Pharmacy
6.3.3. Online Pharmacy
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Prophylactic HIV Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Prophylactic HIV Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Prophylactic HIV Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Prophylactic HIV Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Prophylactic HIV Drug Demand Share Forecast, 2019-2026
9. North America Prophylactic HIV Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Prophylactic HIV Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Prophylactic HIV Drug Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacy
9.4.2. Retail Pharmacy
9.4.3. Online Pharmacy
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Prophylactic HIV Drug Market Size and Volume Forecast by Type
9.7.1. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
9.7.2. Integrase Inhibitor
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Prophylactic HIV Drug Demand Share Forecast, 2019-2026
10. Latin America Prophylactic HIV Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Prophylactic HIV Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Prophylactic HIV Drug Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacy
10.4.2. Retail Pharmacy
10.4.3. Online Pharmacy
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Prophylactic HIV Drug Market Size and Volume Forecast by Type
10.7.1. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
10.7.2. Integrase Inhibitor
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Prophylactic HIV Drug Demand Share Forecast, 2019-2026
11. Europe Prophylactic HIV Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Prophylactic HIV Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Prophylactic HIV Drug Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacy
11.4.2. Retail Pharmacy
11.4.3. Online Pharmacy
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Prophylactic HIV Drug Market Size and Volume Forecast by Type
11.7.1. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
11.7.2. Integrase Inhibitor
11.8. Bass Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Prophylactic HIV Drug Demand Share, 2019-2026
12. Asia Pacific Prophylactic HIV Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Prophylactic HIV Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Prophylactic HIV Drug Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacy
12.4.2. Retail Pharmacy
12.4.3. Online Pharmacy
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Prophylactic HIV Drug Market Size and Volume Forecast by Type
12.7.1. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
12.7.2. Integrase Inhibitor
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Prophylactic HIV Drug Demand Share, 2019-2026
13. Middle East & Africa Prophylactic HIV Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Prophylactic HIV Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Prophylactic HIV Drug Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacy
13.4.2. Retail Pharmacy
13.4.3. Online Pharmacy
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Prophylactic HIV Drug Market Size and Volume Forecast by Type
13.7.1. Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI)
13.7.2. Integrase Inhibitor
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Prophylactic HIV Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Prophylactic HIV Drug Market: Market Share Analysis
14.2. Prophylactic HIV Drug Distributors and Customers
14.3. Prophylactic HIV Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Gilead Sciences
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mylan
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Cipla
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bristol-Myers Squibb
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Roche
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
